Skip to main content

Table 2 Experimental design

From: Immunocontraceptive potential of a GnRH receptor-based fusion recombinant protein

Group

Dose

Method of administration

Group I

50 μg GVAC08

Intradermal

Group II

100 μg GVAC08

Intradermal

Group III (control)

100 μl Saline

Intradermal